Nonalcoholic fatty liver disease is the leading cause of chronic liver disease. Genetic
predisposition, lifestyle, and metabolic comorbidities concur to nonalcoholic fatty liver
disease development and progression to nonalcoholic steatohepatitis, cirrhosis, and
hepatocellular carcinoma. Improvement in risk stratification and development of effective
therapies for nonalcoholic steatohepatitis are key unmet clinical needs. Knowledge
emerging from genomics could meet this need. A polygenic risk score (PRS) is calculated by …